Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biologic drug
|
| gptkbp:activeDuring |
tildrakizumab
|
| gptkbp:administrativeDivision |
self-administered
|
| gptkbp:chemicalFormula |
C_22H_25N_3O_5S
|
| gptkbp:clinicalTrials |
Randomized controlled trials
Phase 3 Efficacy studies Cohort studies Long-term safety studies chronic inflammatory skin disease |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
active infections
hypersensitivity to tildrakizumab |
| gptkbp:date |
2018-03-23
|
| gptkbp:dosageForm |
solution
|
| gptkbp:firstAppearance |
gptkb:FDA
|
| gptkbp:formulation |
sterile solution for injection
|
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ilumya
|
| gptkbp:is_monitored_by |
regular follow-up required
|
| gptkbp:launchSite |
upper arm
once every 12 weeks after initial doses thigh or abdomen |
| gptkbp:mandates |
moderate to severe plaque psoriasis
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:name |
not on WHO Model List of Essential Medicines
|
| gptkbp:notableFeature |
gptkb:Tremfya
gptkb:Guselkumab gptkb:Secukinumab Skyrizi Risankizumab Cosentyx |
| gptkbp:offers |
varies by region
|
| gptkbp:operates_in |
L04AC12
|
| gptkbp:patentStatus |
patented
|
| gptkbp:receives_funding_from |
insurance coverage may vary
|
| gptkbp:researchAreas |
ongoing studies
|
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sells |
gptkb:Ilumya
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
headache nausea injection site reactions upper respiratory infections |
| gptkbp:storage |
store in refrigerator
|
| gptkbp:triggerType |
IL-23 inhibitor
|
| gptkbp:usedFor |
treatment of plaque psoriasis
|